# A personal perspective of patient-centred clinical trials

**Authors:** Trevor Tyne, Elizabeth Ivimey, Leanne Duggan, Jia Liu

PMC · DOI: 10.18632/oncotarget.28776 · Oncotarget · 2025-11-14

## TL;DR

This paper shares the experiences of three patients in early phase trials, highlighting the benefits and challenges they faced and suggesting ways to improve the trial process for patients.

## Contribution

The paper introduces patient-centric innovations like trial navigators and flexible enrollment criteria to enhance early phase trial experiences.

## Key findings

- Patients benefit from access to novel therapies and close monitoring in early phase trials.
- Challenges include strict eligibility criteria, financial burdens, and communication issues.
- Solutions like trial navigators and improved communication training are proposed to enhance patient experience.

## Abstract

Key objective: To illustrate the first-hand journey of three early phase trial participants highlighting their benefits and challenges of participation and patient-centric innovations required to improve trial experience.

Knowledge generated: Early phase trials have traditionally centred on dose-finding and toxicity. However as they have increased in number and improved in therapeutic intent, the patient experience becomes increasingly important. This article illustrates benefits of participation including access to novel therapies, support and close monitoring but challenges around eligibility criteria, finances, and communication. Proposed solutions including trial navigators, enhanced communication training, and greater flexibility in enrolment criteria to improve trials access.

## Full-text entities

- **Diseases:** toxicity (MESH:D064420)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12758155/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12758155/full.md

---
Source: https://tomesphere.com/paper/PMC12758155